Florence Thirion

Florence Thirion

Auto-generated profile, based on publicly available information

Florence Thirion

Université Paris-Saclay, INRAE, MGP

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
YFYong Fan
Yong Fan
RSRené Klinkby Klinkby Støving
René Klinkby Klinkby Støving
SISamar Berreira Ibraim
Samar Berreira Ibraim
THTuulia Hyötyläinen
Tuulia Hyötyläinen
FTFlorence Thirion
Florence Thirion
OPOluf Pedersen
Oluf Pedersen
Anorexia nervosa (AN) is an eating disorder with a high mortality. About 95% of cases are women and it has a population prevalence of about 1%, but evidence-based treatment is lacking. The pathogenesis of AN probably involves genetics and various environmental factors, and an altered gut microbiota has been observed in individuals with AN using amplicon sequencing and relatively small cohorts. Here we investigated whether a disrupted gut microbiota contributes to AN pathogenesis. Shotgun metagenomics and metabolomics were performed on faecal and serum samples, respectively, from a cohort of 77 females with AN and 70 healthy females. Multiple bacterial taxa (for example,Clostridiumspecies) were altered in AN and correlated with estimates of eating behaviour and mental health. The gut virome was also altered in AN including a reduction in viral–bacterial interactions. Bacterial functional modules associated with the degradation of neurotransmitters were enriched in AN and various structural variants in bacteria were linked to metabolic features of AN. Serum metabolomics revealed an increase in metabolites associated with reduced food intake (for example, indole-3-propionic acid). Causal inference analyses implied that serum bacterial metabolites are potentially mediating the impact of an altered gut microbiota on AN behaviour. Further, we performed faecal microbiota transplantation from AN cases to germ-free mice under energy-restricted feeding to mirror AN eating behaviour. We found that the reduced weight gain and induced hypothalamic and adipose tissue gene expression were related to aberrant energy metabolism and eating behaviour. Our ‘omics’ and mechanistic studies imply that a disruptive gut microbiome may contribute to AN pathogenesis.

10 February 2022 in Biological Psychiatry Global Open Science
Verified
Journal Article
Open access
FTFlorence Thirion
Florence Thirion
HSHelene Speyer
Helene Speyer
THTue Haldor Hansen
Tue Haldor Hansen
TNTrine Nielsen
Trine Nielsen
YFYong Fan
Yong Fan
SEStanislav D. Ehrlich
Stanislav D. Ehrlich
Schizophrenia (SCZ) is a heterogeneous neuropsychiatric disorder for which current treatment has insufficient efficacy and severe adverse effects. The modifiable gut microbiome might be a potential target for intervention to improve neurobiological functions through the gut-microbiome-brain axis. In this case-control study, gut microbiota of 132 patients with SCZ and increased waist circumference were compared with gut microbiota of two age- and sex-matched control groups, composed of 132 healthy individuals and 132 individuals with metabolic syndrome. Shotgun sequencing was used to characterize fecal samples at the taxonomic and functional levels. Cognition of the patients with SCZ was evaluated using the Brief Assessment of Cognition instrument. SCZ gut microbiota differed significantly from those of healthy control subjects and individuals with metabolic syndrome in terms of richness and global composition. SCZ gut microbiota were notably enriched in Flavonifractor plautii, Collinsella aerofaciens, Bilophila wadsworthia, and Sellimonas intestinalis, while depleted in Faecalibacterium prausnitzii, Ruminococcus lactaris, Ruminococcus bicirculans, and Veillonella rogosae. Functional potential of the gut microbiota accounted for 11% of cognition variability. In particular, the bacterial functional module for synthesizing tyrosine, a precursor for dopamine, was in SCZ cases positively associated with cognitive score (ρ = 0.34, q ≤ .1). Overall, this study shows that the gut microbiome of patients with SCZ differs greatly from that of healthy control subjects or individuals with metabolic syndrome. Cognitive function of patients with SCZ is associated with the potential for gut bacterial biosynthesis of tyrosine, a precursor for dopamine, suggesting that gut microbiota might be an intervention target for alleviation of cognitive dysfunction in SCZ.

3 June 2025 in Gut
Verified
Journal Article
Open access
PDF file
MLManolo Laiola
Manolo Laiola
Laetitia KOPPELaetitia KOPPE
Laetitia KOPPE
ALAmine Larabi
Amine Larabi
FTFlorence Thirion
Florence Thirion
CLCéline Lange
Céline Lange
SWSandra Wagner
Sandra Wagner
Background: The gut microbiota has been linked to non-communicable diseases, including chronic kidney disease (CKD). However, the relationships between gut microbiome composition changes, uraemic toxins (UTs) accumulation, and diet on CKD severity and progression remain underexplored. Objective: To characterise relationships between gut microbiome composition and functionality, UTs diet, and CKD severity and progression, as well as assess microbial contributions to UTs accumulation through mice faecal microbiota transplantation (FMT). Design: This study profiled the gut microbiome of 240 non-dialysis patients with CKD (CKD-REIN cohort) using shotgun metagenomics, with follow-up in 103 patients after 3 years, with comparisons with healthy volunteers from the Milieu Intérieur cohort. A multiomics approach identifies features associated with CKD severity (and progression), with validation in an independent Belgian cohort. Experimental models used FMT to test CKD gut microbiome effects on UTs and kidney fibrosis. Changes in gut microbiome over time were evaluated, and the impact of diet on these changes was assessed. Results: Compared with matched healthy controls, patients with CKD exhibited gut microbiota alteration, with enrichment of UT precursor-producing species. Patients with severe CKD exhibited higher UT levels and greater enrichment of UT (precursor)-producing species in the microbiota than patients with moderate CKD. Over time, UT (precursor)-producing species increased, and a plant-based low protein diet appeared to mitigate these changes. FMT from patients with CKD to antibiotic-treated CKD model mice increased serum UT levels and exacerbated kidney fibrosis. Conclusions: This study highlights the role of the microbiome and UTs in CKD, suggesting a potential therapeutic target to slow disease progression.

12 June 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NCNathalie Coutry
Nathalie Coutry
JNJulie Nguyen
Julie Nguyen
SSSalima Soualhi
Salima Soualhi
FGFrançois Gerbe
François Gerbe
VMVictoria Meslier
Victoria Meslier
PJPhilippe Jay
Philippe Jay
Gut microbiota imbalance (dysbiosis) is increasingly associated with pathological conditions, both within and outside the gastrointestinal tract. Intestinal Paneth cells are considered to be guardians of the gut microbiota, but the events linking Paneth cell dysfunction with dysbiosis remain unclear. We report a three-step mechanism for dysbiosis initiation. Initial alterations in Paneth cells, as frequently observed in obese and inflammatorybowel diseases patients, cause a mild remodeling of microbiota, with amplification of succinate-producing species. SucnR1-dependent activation of epithelial tuft cells triggers a type 2 immune response that, in turn, aggravates the Paneth cell defaults, promoting dysbiosis and chronic inflammation. We thus reveal a function of tuft cells in promoting dysbiosis following Paneth cell deficiency and an unappreciated essential role of Paneth cells in maintaining a balanced microbiota to prevent inappropriate activation of tuft cells and deleterious dysbiosis. This succinate–tuft cell inflammation circuit may also contribute to the chronic dysbiosis observed in patients.

27 May 2026 in Gut Microbes
Verified
Journal Article
Open access
GLGaïa Lépine
Gaïa Lépine
ADAnne-Marie Davila
Anne-Marie Davila
GCGwendal Cueff
Gwendal Cueff
GPGisèle Pickering
Gisèle Pickering
FIFarid ichou
Farid ichou
Sergio PolakofSergio Polakof
Sergio Polakof
Western dietary patterns, characterized by high intakes of red and processed meat, saturated fat, and refined carbohydrates, contribute substantially to the global burden of cardiometabolic disease...

20 May 2026 in Gut Microbes Reports
Verified
Journal Article
Open access
CBChristelle Bressuire
Christelle Bressuire
FTFlorence Thirion
Florence Thirion
LCLaura Chiaravano
Laura Chiaravano
SNSerigne Inssa Ngom
Serigne Inssa Ngom
RMRomane Marion
Romane Marion
CBChristel Béra-Maillet
Christel Béra-Maillet
Short-chain fructo-oligosaccharides (scFOS) are prebiotic fiber rapidly fermented in the colon and known to stimulate beneficial bacteria, such as Bifidobacterium spp. and Lactobacillaceae. While their overall effects on the gut microbiota are established, the dose–response relationship remained only partially characterized. This study aimed to determine the minimum effective dose of scFOS required to modulate gut microbiota composition and functions. An ex vivo chemostat model was used to simulate colonic fermentation with different doses of scFOS (1 to 10 g/d). Microbiota composition and metabolic activity were assessed by qPCR, short-chain fatty acid (SCFA) quantification, and shotgun metagenomics. An increase in scFOS dose led to higher SCFA levels, particularly acetate and butyrate, along with a modification in microbial composition, with a minimum significant effective dose of 2.5 g/d. Significant increase in Bifidobacterium adolescentis, Anaerostipes hadrus, and Clostridium innocuum was observed at the same dose. Functional analysis revealed an enrichment of GH32 genes in the pangenomes of species positively impacted by scFOS. These findings demonstrate that low doses of scFOS can effectively modulate the gut microbiota and enhance SCFA production, supporting their use in dietary interventions aimed at improving intestinal health.